alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Huntington Disease in 12 studies
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Huntington's disease is a dominantly inherited, progressive neurodegenerative disorder causing marked pathology in the basal ganglia." | 1.28 | Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. ( Dure, LS; Penney, JB; Young, AB, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kolodziejczyk, K | 1 |
| Parsons, MP | 1 |
| Southwell, AL | 1 |
| Hayden, MR | 2 |
| Raymond, LA | 1 |
| Ortiz, AN | 1 |
| Kurth, BJ | 1 |
| Osterhaus, GL | 1 |
| Johnson, MA | 1 |
| Simmons, DA | 1 |
| Mehta, RA | 1 |
| Lauterborn, JC | 1 |
| Gall, CM | 1 |
| Lynch, G | 1 |
| André, VM | 1 |
| Cepeda, C | 2 |
| Venegas, A | 1 |
| Gomez, Y | 1 |
| Levine, MS | 2 |
| Wagster, MV | 1 |
| Hedreen, JC | 1 |
| Peyser, CE | 1 |
| Folstein, SE | 1 |
| Ross, CA | 1 |
| Kremer, B | 1 |
| Tallaksen-Greene, SJ | 1 |
| Albin, RL | 1 |
| Calabresi, P | 1 |
| Centonze, D | 1 |
| Pisani, A | 1 |
| Sancesario, G | 1 |
| Gubellini, P | 1 |
| Marfia, GA | 1 |
| Bernardi, G | 1 |
| Canals, JM | 1 |
| Marco, S | 1 |
| Checa, N | 1 |
| Michels, A | 1 |
| Pérez-Navarro, E | 1 |
| Arenas, E | 1 |
| Alberch, J | 1 |
| Ariano, MA | 1 |
| Calvert, CR | 1 |
| Flores-Hernández, J | 1 |
| Chandler, SH | 1 |
| Leavitt, BR | 1 |
| Cotton, P | 1 |
| Dure, LS | 1 |
| Young, AB | 1 |
| Penney, JB | 1 |
| Beal, MF | 1 |
| Ferrante, RJ | 1 |
| Swartz, KJ | 1 |
| Kowall, NW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NMDA-Receptor Blockade in Huntington's Chorea[NCT00001930] | Phase 2 | 25 participants | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Huntington Disease
| Article | Year |
|---|---|
Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; CA1 Region, Hippocampal; Cell Mem | 2014 |
Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; alpha-Methyltyrosine; Animals; Biophysics; | 2010 |
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Dyskinesia Agents; Corpus St | 2011 |
Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Barium; Benzothiadiazines; Cerebr | 2006 |
Selective loss of [3H]kainic acid and [3H]AMPA binding in layer VI of frontal cortex in Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Autoradiography; Frontal Lobe; Humans; Hun | 1994 |
AMPA and NMDA binding sites in the hypothalamic lateral tuberal nucleus: implications for Huntington's disease.
Topics: Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Glutamates; Glutamic Acid; Humans; H | 1993 |
Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain Ischemia; Cells, Cultured; | 1998 |
Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain-Derived Neurotrophic Factor | 1998 |
NMDA receptor function in mouse models of Huntington disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Calcium Channel | 2001 |
Neuroscientists begin to piece together more parts of Huntington's disease puzzle.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biomarkers; Brain Chemistry; Dise | 1992 |
Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
Topics: Adolescent; Adult; Age Factors; Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Bind | 1991 |
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Atrophy; Biogenic Amines; Cerebra | 1991 |